{"name":"B. Braun Melsungen AG","slug":"b-braun-melsungen-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"Balanced gelatine solution","genericName":"Balanced gelatine solution","slug":"balanced-gelatine-solution","indication":"Hypovolemia and volume replacement during surgery and critical illness","status":"marketed"},{"name":"Lipoplus","genericName":"Lipoplus","slug":"lipoplus","indication":"Other","status":"marketed"},{"name":"MLF 541","genericName":"MLF 541","slug":"mlf-541","indication":"Other","status":"phase_3"},{"name":"balanced electrolyte solution","genericName":"balanced electrolyte solution","slug":"balanced-electrolyte-solution","indication":"Other","status":"marketed"},{"name":"Albumin + electrolyte solution","genericName":"Albumin + electrolyte solution","slug":"albumin-electrolyte-solution","indication":"Hypovolemia and hypoproteinemia in critically ill patients","status":"marketed"},{"name":"HES 6%","genericName":"HES 6%","slug":"hes-6","indication":"Other","status":"marketed"},{"name":"Lipidem","genericName":"Lipidem","slug":"lipidem","indication":"Other","status":"marketed"},{"name":"Lipofundin MCT","genericName":"Lipofundin MCT","slug":"lipofundin-mct","indication":"Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition","status":"marketed"},{"name":"Lipofundin MCT 20%","genericName":"Lipofundin MCT 20%","slug":"lipofundin-mct-20","indication":"Parenteral nutrition in patients unable to maintain adequate oral or enteral intake","status":"marketed"},{"name":"Lipofundin N 20%","genericName":"Lipofundin N 20%","slug":"lipofundin-n-20","indication":"Parenteral nutrition in patients unable to maintain adequate oral or enteral intake","status":"marketed"},{"name":"Lipoplus 20%","genericName":"Lipoplus 20%","slug":"lipoplus-20","indication":"Parenteral nutrition in patients unable to maintain adequate oral/enteral intake","status":"marketed"},{"name":"MCT/LCT containing lipid emulsion","genericName":"MCT/LCT containing lipid emulsion","slug":"mct-lct-containing-lipid-emulsion","indication":"Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition","status":"phase_3"},{"name":"NuTRIflex Lipid peri","genericName":"NuTRIflex Lipid peri","slug":"nutriflex-lipid-peri","indication":"Perioperative nutritional support in patients unable to receive oral or enteral nutrition","status":"phase_3"},{"name":"Propofol 1%","genericName":"Propofol 1%","slug":"propofol-1","indication":"Induction and maintenance of general anesthesia","status":"marketed"},{"name":"compounded monobag","genericName":"compounded monobag","slug":"compounded-monobag","indication":"Customized medication delivery for various medical conditions","status":"phase_3"},{"name":"propofol (drug)","genericName":"propofol (drug)","slug":"propofol-drug","indication":"General anesthesia","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"Gelaspan 4%","genericName":"Gelaspan 4%","slug":"gelaspan-4","indication":"Acute blood loss and hypovolemic shock requiring volume replacement","status":"phase_3"},{"name":"Gelofusine 4%","genericName":"Gelofusine 4%","slug":"gelofusine-4","indication":"Acute hypovolemia and restoration of circulating blood volume in surgery and trauma","status":"phase_3"},{"name":"Gelofusine balanced","genericName":"Gelofusine balanced","slug":"gelofusine-balanced","indication":"Acute hypovolemia and blood loss requiring volume replacement during surgery or trauma","status":"phase_3"},{"name":"HES 10%","genericName":"HES 10%","slug":"hes-10","indication":"Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma","status":"marketed"},{"name":"HES 130/0.42 + electrolyte solution","genericName":"HES 130/0.42 + electrolyte solution","slug":"hes-130-0-42-electrolyte-solution","indication":"Acute hypovolemia and restoration of circulating blood volume in surgical and trauma patients","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Nutriflex Omega special + Oxepa","genericName":"Nutriflex Omega special + Oxepa","slug":"nutriflex-omega-special-oxepa","indication":"Nutritional support in critically ill patients","status":"phase_3"},{"name":"Nutriflex Lipid special + Pulmocare","genericName":"Nutriflex Lipid special + Pulmocare","slug":"nutriflex-lipid-special-pulmocare","indication":"Nutritional support in patients with pulmonary disease or respiratory compromise requiring parenteral nutrition","status":"phase_3"}]}],"pipeline":[{"name":"Balanced gelatine solution","genericName":"Balanced gelatine solution","slug":"balanced-gelatine-solution","phase":"marketed","mechanism":"Balanced gelatine solution provides fluid resuscitation and volume expansion by delivering a colloid suspension that maintains oncotic pressure and restores intravascular volume.","indications":["Hypovolemia and volume replacement during surgery and critical illness","Perioperative fluid resuscitation"],"catalyst":""},{"name":"Lipoplus","genericName":"Lipoplus","slug":"lipoplus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MLF 541","genericName":"MLF 541","slug":"mlf-541","phase":"phase_3","mechanism":"MLF 541 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"Nutriflex Omega special + Oxepa","genericName":"Nutriflex Omega special + Oxepa","slug":"nutriflex-omega-special-oxepa","phase":"phase_3","mechanism":"Nutriflex Omega special + Oxepa is a parenteral nutrition formulation that provides essential fatty acids, amino acids, and micronutrients to support metabolic function and reduce inflammatory markers in critically ill patients.","indications":["Nutritional support in critically ill patients","Acute respiratory distress syndrome (ARDS)","Sepsis and systemic inflammatory response"],"catalyst":""},{"name":"balanced electrolyte solution","genericName":"balanced electrolyte solution","slug":"balanced-electrolyte-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Albumin + electrolyte solution","genericName":"Albumin + electrolyte solution","slug":"albumin-electrolyte-solution","phase":"marketed","mechanism":"This product provides albumin protein and essential electrolytes to restore intravascular volume and maintain electrolyte balance in patients with fluid loss or hypoproteinemia.","indications":["Hypovolemia and hypoproteinemia in critically ill patients","Volume replacement in severe burns","Hemorrhagic shock","Perioperative fluid management"],"catalyst":""},{"name":"Gelaspan 4%","genericName":"Gelaspan 4%","slug":"gelaspan-4","phase":"phase_3","mechanism":"Gelaspan 4% is a gelatin-based plasma volume expander that increases and maintains circulating blood volume through colloidal osmotic pressure.","indications":["Acute blood loss and hypovolemic shock requiring volume replacement","Perioperative volume management"],"catalyst":""},{"name":"Gelofusine 4%","genericName":"Gelofusine 4%","slug":"gelofusine-4","phase":"phase_3","mechanism":"Gelofusine 4% is a plasma volume expander that increases and maintains circulating blood volume by providing a colloidal solution that draws and retains fluid in the intravascular space.","indications":["Acute hypovolemia and restoration of circulating blood volume in surgery and trauma","Perioperative fluid replacement"],"catalyst":""},{"name":"Gelofusine balanced","genericName":"Gelofusine balanced","slug":"gelofusine-balanced","phase":"phase_3","mechanism":"Gelofusine balanced is a colloid plasma volume expander that restores and maintains circulating blood volume in hypovolemic patients.","indications":["Acute hypovolemia and blood loss requiring volume replacement during surgery or trauma","Hypovolemic shock management"],"catalyst":""},{"name":"HES 10%","genericName":"HES 10%","slug":"hes-10","phase":"marketed","mechanism":"HES 10% is a hydroxyethyl starch colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance.","indications":["Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma","Perioperative fluid management in patients undergoing major surgery"],"catalyst":""},{"name":"HES 130/0.42 + electrolyte solution","genericName":"HES 130/0.42 + electrolyte solution","slug":"hes-130-0-42-electrolyte-solution","phase":"marketed","mechanism":"HES 130/0.42 is a synthetic colloid that expands intravascular volume and maintains oncotic pressure to restore and maintain circulating blood volume in hypovolemic patients.","indications":["Acute hypovolemia and restoration of circulating blood volume in surgical and trauma patients","Perioperative fluid management in patients requiring volume replacement"],"catalyst":""},{"name":"HES 6%","genericName":"HES 6%","slug":"hes-6","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lipidem","genericName":"Lipidem","slug":"lipidem","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lipofundin MCT","genericName":"Lipofundin MCT","slug":"lipofundin-mct","phase":"marketed","mechanism":"Lipofundin MCT is a lipid emulsion that provides essential fatty acids and calories as a component of parenteral nutrition.","indications":["Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition","Provision of essential fatty acids and energy in critically ill or post-operative patients"],"catalyst":""},{"name":"Lipofundin MCT 20%","genericName":"Lipofundin MCT 20%","slug":"lipofundin-mct-20","phase":"marketed","mechanism":"Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.","indications":["Parenteral nutrition in patients unable to maintain adequate oral or enteral intake","Prevention of essential fatty acid deficiency during prolonged parenteral nutrition","Nutritional support in post-operative and critically ill patients"],"catalyst":""},{"name":"Lipofundin N 20%","genericName":"Lipofundin N 20%","slug":"lipofundin-n-20","phase":"marketed","mechanism":"Lipofundin N 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.","indications":["Parenteral nutrition in patients unable to maintain adequate oral or enteral intake","Post-operative nutritional support","Critical illness requiring intravenous nutritional supplementation"],"catalyst":""},{"name":"Lipoplus 20%","genericName":"Lipoplus 20%","slug":"lipoplus-20","phase":"marketed","mechanism":"Lipoplus 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat orally.","indications":["Parenteral nutrition in patients unable to maintain adequate oral/enteral intake","Prevention of essential fatty acid deficiency in long-term parenteral nutrition"],"catalyst":""},{"name":"MCT/LCT containing lipid emulsion","genericName":"MCT/LCT containing lipid emulsion","slug":"mct-lct-containing-lipid-emulsion","phase":"phase_3","mechanism":"A lipid emulsion combining medium-chain triglycerides (MCT) and long-chain triglycerides (LCT) that provides essential fatty acids and calories for parenteral nutrition.","indications":["Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition","Provision of essential fatty acids and calories in critically ill or post-operative patients"],"catalyst":""},{"name":"NuTRIflex Lipid peri","genericName":"NuTRIflex Lipid peri","slug":"nutriflex-lipid-peri","phase":"phase_3","mechanism":"NuTRIflex Lipid peri is a parenteral nutrition emulsion that provides essential lipids, amino acids, and other nutrients for perioperative nutritional support in patients unable to eat normally.","indications":["Perioperative nutritional support in patients unable to receive oral or enteral nutrition"],"catalyst":""},{"name":"Nutriflex Lipid special + Pulmocare","genericName":"Nutriflex Lipid special + Pulmocare","slug":"nutriflex-lipid-special-pulmocare","phase":"phase_3","mechanism":"Nutriflex Lipid special + Pulmocare is a parenteral nutrition formulation designed to provide comprehensive macronutrient and micronutrient support optimized for patients with pulmonary disease or respiratory compromise.","indications":["Nutritional support in patients with pulmonary disease or respiratory compromise requiring parenteral nutrition","Support for mechanically ventilated patients or those at risk of respiratory failure"],"catalyst":""},{"name":"Propofol 1%","genericName":"Propofol 1%","slug":"propofol-1","phase":"marketed","mechanism":"Propofol is a rapid-acting intravenous anesthetic that enhances inhibitory GABA neurotransmission in the central nervous system, producing sedation and unconsciousness.","indications":["Induction and maintenance of general anesthesia","Sedation in mechanically ventilated patients in intensive care units","Sedation for diagnostic and therapeutic procedures"],"catalyst":""},{"name":"compounded monobag","genericName":"compounded monobag","slug":"compounded-monobag","phase":"phase_3","mechanism":"Compounded monobags are customized sterile solutions used to deliver medications directly to patients.","indications":["Customized medication delivery for various medical conditions"],"catalyst":""},{"name":"propofol (drug)","genericName":"propofol (drug)","slug":"propofol-drug","phase":"phase_3","mechanism":"Propofol is a short-acting sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia.","indications":["General anesthesia","Sedation for mechanical ventilation","Sedation for diagnostic or surgical procedures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQm1oQ3dCV0cwQnF2aFgxSGQzMm05TjB0WG41VVhUeUFGdnF2b19fa3ZRYWZqR0xTblRrQVNHTHQ5SE12WlhNNUpDRlZ5WFZBRl9BX0JwcUpRQzVXaWJLUlBmSmhJWWpBdGZQMnpQaXVJczJmM0oyYk5qR2tPV2Q1VDRkU0MwRlo2ZXdLWHUtdTZibTBjdTlJS1huYVVmVzdVM0dEakJXbEhwaWxDUlZVeWthNFpYdXpTNF9uVnR6N0pRUEhhbktiZE9uMW1RQWtUNWNLMw?oc=5","date":"2026-04-05","type":"pipeline","source":"IndexBox","summary":"Pharmaceutical Grade Sodium Chloride Market Forecast Points Higher Toward 2035, Driven by Biologics Expansion - IndexBox","headline":"Pharmaceutical Grade Sodium Chloride Market Forecast Points Higher Toward 2035, Driven by Biologics Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZWl5UmpiNFh6NUl2TVRSVWZTYTFqcVd5a04wbC1Fd3M0MVdVY3VYbllVSHNyOUh1Mjh3TE56a0JHTmhWTk9UWjZRdnk3TUhWQ2NBQ3BtUkh0LTBZajAyZUhkQUY2SEh1a1VyS3JDcDhROS1mUWpvUVhzZzJyY0M4Yk80YVVneEhPQmNUcmIxU0gzVG04?oc=5","date":"2026-04-01","type":"pipeline","source":"openPR.com","summary":"Future Perspectives: Key Trends Shaping the Intravenous Therapy Solutions Market Up to 2030 - openPR.com","headline":"Future Perspectives: Key Trends Shaping the Intravenous Therapy Solutions Market Up to 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQci1KaDBoQnI2a2FhTXBCbWJxamNkaGpZOHNSdTNJWURNRjc3MTJ4YUR2Rm1XczQtX2w2Wmg5SmJXY05VSERRbFdKUERFcS1fNFBjUmJicm5uMWE3QVF1TnRNT3ZRckxxYk11bU0wRE1kM2Y2bHJZNGJSOEh3UTZ2U19GUEdRbmsyWVc0S21rQWtnb2tqWGdpVkVUM0RWckdaM1diaXN3WmpSNExCTFNldTRMbmxLdmdfVlZYeHJJUFpxZ3VCT2Q5QkpPeGpSYm84ekQzZGs4NmxWYzFwSlZyVDlwa2RIWmk1RjV1amREemlDYzVhRF9nZzBORTFFQXEwcXdTeEVXajNSaUEtWC04bjlmTDRaRUl2MEVHQVJraXZRb3NzdktWUEVjc01oemJSSEtkZVlhazhLTURwTDNjbGlpSVVvcV9hakE?oc=5","date":"2026-03-25","type":"pipeline","source":"PR Newswire UK","summary":"Peptide Therapeutics Market Growing at 7.16% CAGR to Reach USD 70.20 Bn by 2031 Driven by Rising Cancer Prevalence & Metabolic Disorder Burden, Reports Mordor Intelligence - PR Newswire UK","headline":"Peptide Therapeutics Market Growing at 7.16% CAGR to Reach USD 70.20 Bn by 2031 Driven by Rising Cancer Prevalence & Met","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBkRnpGWjlsdllTM0hsaGdKUE9NZTRlNDkwV25GZUZGamEwMGlQZUw5SzZMd1duT1lxcjJ1Y1hrbVp5eTh0c1MtdUhQUXUtQ2xwU1dlRkJXWS1wLUVtOVhaM2g3RzhMaUYxNi1YNF8wdFdnT0tGODNz?oc=5","date":"2025-12-09","type":"pipeline","source":"Fact.MR","summary":"Diabetic Ketoacidosis Treatment Market | Global Market Analysis Report - 2035 - Fact.MR","headline":"Diabetic Ketoacidosis Treatment Market | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNOXlWc01aQm9IWUd2akNhMUdSb056YTI1MmJDbG9aN0tiWDhzQ2IyYXVzb3dMUU5kVjdHS3RrZHY3WFRTVHdQWUtLSXM1N2pCdklIVUdIY0tmbk0tQjZ0YlRaemY4NGNlbG9sejhTdHVzOWdyeVNrQXNTSjVVZFBzaUY5aU5JQ1F3RWFVeVVodXVURV9Bd2d3VzR4NEsyRi1KUFNrMF9hNDAxT1lVd0Q5UHdpcmVUOVZYM2fSAXJBVV95cUxOSmF3QnhWc3NYRXY2V3N4eDN5OFJKbWwxcGo4QmIyX0FuWFpwQ3U4cnlNMFRlQ2JvOU94WW1QV1o5a2dGVjRvOVdxc19LYVc2anhhU1BxMnZMZ1puazctc2V3cmpDQzhLZnpMZkZuTm1jWWc?oc=5","date":"2025-11-17","type":"deal","source":"Law360","summary":"B. Braun Unit Inks $38.5M Deal To End FCA Knee Implant Case - Law360","headline":"B. Braun Unit Inks $38.5M Deal To End FCA Knee Implant Case - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5JeXhjb3FhSWdOY0RJX3pOUlhnNk5ObVdBcGZsbUY5TnFKRnRqSTNNNGdmaFFOOWI2aWZjcmY2cUQtMWh4djc0SjJEZVBZSFpEaFJ1dzRTcmdxNUtDOUJaS21BdGdSZ2ZITUxrR0tsVk9oYjhJYTMzakpHNA?oc=5","date":"2025-10-20","type":"pipeline","source":"researchnester.com","summary":"Parenteral Nutrition Market Size & Share, Growth Report 2035 - researchnester.com","headline":"Parenteral Nutrition Market Size & Share, Growth Report 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPb2pHNmgwTFdCQmhwZXFxQmw3cUhhb2RlTU9iZk81X3ZDalpmWm9rZzFDSlRtU3E3M1RyaW9ZcEpLdkpOelRyYVBYQXdHMndRaXdfdDVxbWI1S3dRR0xkS1RuVTduTkg3R3JITk1Fd2VjRDlZWXhTaFlYWml0alptb0xuTzJkaERxQnpmcW83VnZHUnNOMU8wT2FYTmxETEd1cEEwajlNZWtFMGNtajdMMGVsWG9ubUJqeXNKd3JwcUotb0U?oc=5","date":"2025-09-10","type":"deal","source":"Business Daily","summary":"Court blocks German pharma firm from cutting off Kenyan dealers - Business Daily","headline":"Court blocks German pharma firm from cutting off Kenyan dealers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPY25UdlN1cUZGMV9KUEZnX3ZOdzEwOHJtdURCMElkcXpZMjlSUVExTHJaYS1Ed2pLckVCbi1YNXdJc3gwTDMxNVFmQ3NBcnRGS0hibGNXMmo4SC1CajF5dzRiY2Z2S1JER1J5OE9WUlZIWUtRS01odE1jYkZROWZYdWE2elR0d2pHZWc?oc=5","date":"2025-08-04","type":"pipeline","source":"Orange County Business Journal","summary":"B. Braun Nears Completion of $500M Campus Revamp - Orange County Business Journal","headline":"B. Braun Nears Completion of $500M Campus Revamp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1uaVRFVlU4UmtyR1NPNFk0MEJPblB0TTVoR09iZU9pMVNpdklGRzV0bHU0TEh5cVdCX0F2bGtvR05Db3JmaG15dEZnX05TVmZVWFg0d0FpU1NMSUJtN3pCQzRxZnpZWVJTWHpRNUtTaDVEMnRpNFlZ?oc=5","date":"2024-05-27","type":"pipeline","source":"Medical Device Network","summary":"Medical Device Network Excellence Awards 2024: B. Braun - Medical Device Network","headline":"Medical Device Network Excellence Awards 2024: B. Braun","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQTlpGR2FiYzg3U3h2R2JHYjI2M1FhOWhCZFlZMUJjTnM2WHdKdUlScEhsVkVtQ1AxMUE4dDNVX09aZjFsOUdkWWVSQXpSbUZrS3JUN2dMcTU0bEdGcWkwT2RrRm1zM3VCcE5rczhkQXUtSjhRU2lZUzVGT1FSemdQcldBMTBtNnR0NnhMSkhNZGZQVENvMjljUElENkdCcnZ1ekZrSGFxcW1DcjZJa2dORjRCazczMlBLN0tjVHE0cHFjdUE0UGIydDZpSHJ2VVk?oc=5","date":"2023-11-17","type":"regulatory","source":"Reuters","summary":"FDA identifies recall of B. Braun Medical pump system as most serious - Reuters","headline":"FDA identifies recall of B. Braun Medical pump system as most serious","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNXJpb29jRS1uQ3V4LWZ1OEZIdkJwWkhDd1g2dkplUnZrclhuUnoxWGp1VlhYNVAzTlE5NUpXMG1rQ2wzNkl4N1J3RnRVX0R3N0dQZl9iQ0M4cmExSDhuTzFtTFJTQUotODR4bjBlOEQ4UWtNNXlKWk9zcHBEd083Vg?oc=5","date":"2020-06-05","type":"pipeline","source":"MassDevice","summary":"B. Braun’s top North American executive to retire - MassDevice","headline":"B. Braun’s top North American executive to retire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTHV2c0RfbHFlT2RaZXZWMGtyT255M2xEMVl0eXJWZVpsMjQyck1MZTc3eXBHNkVHeXR1bkhwZGtmN0JkWHBjYjNuWVF5NldEbHdfR0czMGdQOW95MHBIVXIzQnBBanVld01jNU1jUHQ4c1d3SVUwZVBxbUVxSEhqLWc4c1NSc0ZmNE5RWktGQXZvc0pFM0NLNUlNT2MyaXdWVnpuSkpDTGhXVG1CcjhNYldTWWdBZ0RM?oc=5","date":"2015-03-21","type":"pipeline","source":"Forbes","summary":"Eight Billionaires Emerge From German Medical Device Firm B. Braun - Forbes","headline":"Eight Billionaires Emerge From German Medical Device Firm B. Braun","sentiment":"neutral"}],"patents":[],"drugCount":23,"phaseCounts":{"marketed":13,"phase_3":10},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}